Overview
US short-stay surgical facility operator's Q1 revenue rose 4.5%, beating analyst expectations
Adjusted EPS and adjusted EBITDA for Q1 both beat analyst expectations
Company reaffirmed full-year 2026 revenue and adjusted EBITDA guidance
Outlook
Surgery Partners sees 2026 revenue between $3.35 bln and $3.45 bln
Company expects 2026 Adjusted EBITDA of at least $530 mln
Company says cost management and physician recruitment are key to meeting 2026 targets
Result Drivers
REVENUE PER CASE - Q1 same-facility revenue growth was driven by a 3.8% increase in revenue per case
CASE VOLUME - Same-facility cases rose 0.6% year-over-year, contributing to revenue growth
COST MANAGEMENT - Management cited cost management discipline and portfolio optimization as key operational focuses
Company press release: ID:nGNX8CP8dx
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$810.90 mln
$797.89 mln (11 Analysts)
Q1 Adjusted EPS
Beat
-$0.03
-$0.12 (12 Analysts)
Q1 Adjusted EBITDA
Beat
$102.30 mln
$100.79 mln (11 Analysts)
Q1 Adjusted EBITDA Margin
12.60%
Q1 Operating Income
$65.80 mln
Q1 Pretax Profit
-$3.30 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Surgery Partners Inc is $19.00, about 33.8% above its May 4 closing price of $14.20
The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 20 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)